Pfizer is navigating a dramatic financial shift as COVID-19 product revenues plummeted. The company has redeployed its pandemic-era windfall into over $80 billion of acquisitions, with the $40B+ Seagen purchase representing a major bet on Antibody-Drug Conjugates (ADCs) to drive future growth in oncology.
A significant portion of the discussion focuses on the imminent competitive threat from China. Bourla details China's strategic five-year plan, its dominance in scientific publications, its creation of a robust IP protection system, and its operational model of being twice as cheap and three times as fast.
AI is identified as a key driver of future disruption, on par with the geopolitical challenge from China. Pfizer's strategy is not to centralize AI expertise but to decentralize accountability and upskill thousands of employees, aiming to embed AI capabilities across all functions from R&D to commercial.
Pfizer boasts top-quartile technical success, with clinical success rates of 18-19% (vs. 10-11% industry average) and a 95% regulatory approval rate. However, Bourla admits this has not translated into top-quartile financial returns from R&D, indicating a disconnect between scientific achievement and commercial value creation.
Keep pulling the thread on Albert Bourla.